Neuroscience

RAINBOWFISH is an open-label, single-arm, multicenter clinical study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of risdiplam (RG7916) in asymptomatic infants, aged from birth to 6 weeks of age (at first dose) with genetically diagnosed SMA. RAINBOWFISH will provide data on the early administration of RG7916 alongside the ongoing FIREFISH, SUNFISH and JEWELFISH studies.